对2015年版《中国药典》一部成方制剂收载品种遴选的建议

Suggestion on Selection of Chinese Patent Medicine Lists Recorded in Pharmacopoeia of People's Republic of China Volume I(2015 Version)

对2015年版《中国药典》一部成方制剂①收载品种的遴选提出建议,②收载品种与《国家基本药物》、《国家基本医疗保险药品目录》收载品种进行比较;③制剂收载品种含濒危动物及国家保护动物品种情况进行分析;对2010年版《中国药典》临床各科用药收载品种以及民族药收载情况进行分析。《中国药典》品种遴选原则和再评价方法,临床各科用药入选的比例,有关野生濒危动物药及人体组织器官药物入药,民族药品种遴选,收载品种与基本药物、医保药物、濒危品种应用脱节等方面尚存在的问题。建议建立《中国药典》一部成方制剂品种遴选基地;明确制定收载品种遴选的原则,兼顾国家基本药物、医疗保险品种;调整临床各科用药入选的比例,满足临床的需要;含濒危动物及国家保护动物品种严格按国家规定执行;加强民族药品种的入选;加强与国家相关部门的沟通、协商与合作。

Make a suggestion concerning the selection of Chinese Patent Medicine lists recorded in pharmacopoeia of the people＇s republic of China volume I（2015 version）.Analyzing Chinese Patent Medicine lists which contains endangered species and National Protected animals strain,recorded in pharmacopoeia of the people＇s republic of China volume I（2010 version）;Analyzing Clinical Medicine lists and Minority Medicine lists recorded in pharmacopoeia of the people＇s republic of China volume I（2010 version）.The Selection principles and the re-estimation of Species in pharmacopoeia of the people＇s republic of China volume.The proportion of the selection of Clinical medicine.The selection of medicine which contains endangered species and National Protected animals strain.The selection of national medicine.The selection of medicine species has been disconnected with the application of basic medicine,medicare medicine and endangered species.Expect to establish the catalogue of selected medicine concerning the pharmacopoeia of the people＇s republic of China.Make definite and clear of the selection principles of medicine specie,which should conclude the basic medicine and medicare medicine as well.Adjust the proportion of clinical medicine,in order to fulfill the demand of clinical work.The selection of medicine which contains endangered species should obey the law of nation.Acquire more application of traditional national medicine.Confirm more communication and combination with the related Department of medicine in China.